Search results for "Acute disease"

showing 10 items of 430 documents

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

2006

1. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Operative Unit of Gastroenterology, St Camillo-Forlanini Hospital, Rome, Italy. prantera@tin.it BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. AIM: To evaluate the difference in efficacy between once and twice/daily oral administration of rifaximin and placebo in the treatment of active Crohn's …

AdultMalemedicine.medical_specialtyPlacebo-controlled studyCIPROFLOXACINPlaceboGastroenterologyInflammatory bowel diseaseDrug Administration ScheduleRifaximinPlaceboschemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodIntestinal mucosaINFLAMMATORY-BOWEL-DISEASE C-REACTIVE PROTEIN ULCERATIVE-COLITIS METRONIDAZOLE CIPROFLOXACIN MANAGEMENT RECURRENCE DIARRHEA ANTIBODY MODERATEInternal medicinemedicineMANAGEMENTHumansPharmacology (medical)RECURRENCEAntibacterial agentCrohn's diseaseChi-Square DistributionHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.diseaseRifamycinsUlcerative colitisDIARRHEAC-REACTIVE PROTEINAnti-Bacterial AgentsSurgeryRifaximinTreatment OutcomechemistryULCERATIVE-COLITISANTIBODYMETRONIDAZOLEAcute Diseaserifaximin.crohn's diseaseMODERATEFemalebusinessINFLAMMATORY-BOWEL-DISEASE
researchProduct

Hyperuricemia in acute heart failure. More than a simple spectator?

2007

Hyperuricemia is a prevalent condition in chronic heart failure (CHF), describing increased oxidative stress and inflammation. Although there is evidence that serum uric acid (UA) predicts mortality in CHF, its role as a prognostic biomarker in acute heart failure (AHF) has not yet been well assessed. The aim of this study was to determine if UA levels predict all-cause mortality. Additionally, as a secondary endpoint we sought the clinical predictors of UA serum level in this population.We analyzed 560 consecutive patients with AHF admitted in a single university center. UA (mg/dl) was measured during early hospitalization. Patient survival status was followed up after discharge (median fo…

AdultMalemedicine.medical_specialtyPopulationHyperuricemiaGastroenterologychemistry.chemical_compoundPredictive Value of TestsInternal medicineCause of DeathInternal MedicinemedicineHumansHyperuricemiaIntensive care medicineeducationCause of deathAgedProportional Hazards ModelsAged 80 and overHeart Failureeducation.field_of_studybusiness.industryProportional hazards modelMortality ratemedicine.diseasePrognosisUric AcidOxidative StresschemistryPredictive value of testsHeart failureAcute DiseaseMultivariate AnalysisUric acidFemalebusinessFollow-Up StudiesEuropean journal of internal medicine
researchProduct

Association between +1059G/C CRP polymorphism and acute myocardial infarction in a cohort of patients from Sicily: a pilot study.

2006

Inflammation plays a role in all the phases of atherosclerosis, and increased production of the acute-phase reactant, C-reactive protein (CRP), predicts future cardiovascular events. Furthermore, CRP has been claimed to play a role in the pathogenesis of atherosclerosis; therefore, CRP polymorphisms might be associated with acute myocardial infarction (AMI). We have analyzed male patients affected by AMI and healthy age-related male controls from Sicily for +1059G/C CRP single-nucleotide polymorphism (SNP). There was a significantly higher frequency of +1059C SNP (P = 0.0008; OR 3.86) in patients compared to controls. CRP serum levels were significantly higher in C+ healthy subjects rather …

AdultMalemedicine.medical_specialtyPopulationMyocardial InfarctionPilot ProjectsGastroenterologyPolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyPathogenesisCohort StudiesHistory and Philosophy of ScienceGene FrequencyInternal medicinemedicineImmunogeneticsOdds RatioSNPHumansMyocardial infarctioneducationSicilyInflammationeducation.field_of_studyPolymorphism Geneticbusiness.industryGeneral NeuroscienceCase-control studyOdds ratioMiddle Agedmedicine.diseaseSurgeryC-Reactive ProteinCase-Control StudiesCohortAcute DiseasebusinessCohort studyAnnals of the New York Academy of Sciences
researchProduct

Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response

2008

The aim of the present study was to examine the relevance of depressive symptoms during an acute schizophrenic episode for the prediction of treatment response. Two hundred inpatients who fulfilled DSM-IV criteria for schizophrenia or schizophreniform disorders were assessed at hospital admission and after 6 weeks of inpatient treatment using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Rating Scale for Depression (HAM-D). Depressive symptoms showed positive correlations with both positive and negative symptoms at admission and after 6 weeks, and decreased during 6 weeks of treatment. Pronounced depressive symptoms (HAM-D score> or =16) were found in 28% of the sample a…

AdultMalemedicine.medical_specialtyPsychosis610 Medicine & healthComorbidity10056 Clinic for Clinical and Social Psychiatry Zurich West (former)law.invention2738 Psychiatry and Mental Health03 medical and health sciencesPatient Admission0302 clinical medicineRandomized controlled triallawInternal medicinemental disordersmedicineHumansSchizophreniform disorderPsychiatryBiological PsychiatryDepression (differential diagnoses)ProbabilityPsychiatric Status Rating ScalesDepressive DisorderDepressive Disorder MajorPsychotropic DrugsPositive and Negative Syndrome ScaleHamilton Rating Scale for Depressionmedicine.diseaseComorbidity030227 psychiatryDiagnostic and Statistical Manual of Mental DisordersHospitalizationPsychiatry and Mental healthTreatment OutcomePsychotic DisordersSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychology2803 Biological Psychiatry030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up Studies
researchProduct

Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia

2006

This clinical study analyzed gender-specific relationships of depression with other psychopathological and clinical variables in hospitalized patients with schizophrenia. During clinical routine treatment 119 inpatients with acute schizophrenia (DSM-IV) were investigated with the Calgary Depression Rating Scale for Schizophrenia (CDSS), the Clinical Global Impressions (CGI), and the Positive and Negative Syndrome Scale (PANSS). Depression scores of 77 male and 42 female patients (mean age 31.6+/-10.3 years) were related to background variables and to positive and negative symptom scores. Mean CDSS (5.8+/-5.6) and PANSS scores (total 76.9+/-22.1, positive symptoms 17.6+/-7.6, negative sympto…

AdultMalemedicine.medical_specialtyPsychosisAdolescentAcute schizophreniaRating scaleInternal medicinemental disordersmedicineHumansBiological PsychiatryDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesPharmacologySex CharacteristicsPositive and Negative Syndrome ScaleDepressionLength of StayMiddle Agedmedicine.diseaseAntidepressive AgentsHospitalizationSchizophreniaAcute DiseaseSchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychopathologyClinical psychologySex characteristicsProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Outcome of suicidal patients with schizophrenia: results from a naturalistic study.

2010

Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller H-J, Riedel M. Outcome of suicidal patients with schizophrenia: results from a naturalistic study. Objective:  Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences. Method:  Biweekly PANSS (Positive and Negative Syndrome Scale), HAMD (Hamilton Depression Rating Scale) and UKU (Udvalg for Klinske Undersogelser Side Effect Rating Scale) ratings were evaluated in 339 in-patients with schizophrenic spectrum disorder…

AdultMalemedicine.medical_specialtyPsychosisMedizinPoison controlSuicide AttemptedComorbidityAkathisiaCohort StudiesHospitals University03 medical and health sciencesYoung Adult0302 clinical medicineRating scaleRisk FactorsGermanyHamdmedicineHumansPsychiatryPsychiatric Status Rating ScalesDepressive Disorder MajorPositive and Negative Syndrome ScaleIncidenceMiddle Agedmedicine.diseaseComorbidityHealth Surveys3. Good health030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesTreatment OutcomeSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychology030217 neurology & neurosurgeryAkathisia Drug-InducedAntipsychotic AgentsActa psychiatrica Scandinavica
researchProduct

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

2000

Antipsychotic efficacy and side effects of the selective sigma ligand EMD 57445 (panamesine) were investigated in 12 patients (6 males, 6 females) who met DSM-III-R criteria for schizophrenia. A 4-week open clinical study revealed only modest effects of EMD 57445 and its metabolites on positive and negative symptoms of schizophrenia. Extrapyramidal and other side effects were moderate, although a significant increase in mild dyskinetic movements was found. Five patients, four of whom were females, completed the trial. Dropouts were mainly due to treatment failure. Antipsychotic effects were significantly greater in female than male patients.

AdultMalemedicine.medical_specialtyPsychosismedicine.medical_treatmentSigma receptorPanamesineDrug Administration ScheduleBasal Ganglia DiseasesPiperidinesInternal medicinemental disordersmedicineHumansReceptors sigmaAntipsychoticOxazolesBiological PsychiatryBiotransformationAgedPsychiatric Status Rating ScalesDose-Response Relationship DrugMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthEndocrinologyTreatment OutcomeTolerabilityDopamine receptorSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychiatry research
researchProduct

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

2014

Background— Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. Methods and Results— In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.…

AdultMalemedicine.medical_specialtyRE-COVER IIrecurrenceAntagonists & inhibitorsAdolescentvenous thromboembolismAntithrombinsDabigatranYoung AdultDouble-Blind MethodRisk FactorsPhysiology (medical)Internal medicinemedicineHumansdabigatrancardiovascular diseasesantagonists & inhibitorAgedacute venous thromboembolismHeparinbusiness.industryWarfarinFollow up studiesAnticoagulantsantagonists & inhibitors; hemorrhage; recurrence; thrombin; venous thromboembolism; warfarinHeparinHeparin Low-Molecular-WeightMiddle AgedthrombinSettore MED/11 - Malattie Dell'Apparato CardiovascolarewarfarinHeparin.low molecular weightPooled analysisAnesthesiaAcute Diseasebeta-AlanineBenzimidazolesFemaledabigatran; warfarin; acute venous thromboembolism; RE-COVER IIhemorrhageCardiology and Cardiovascular MedicinebusinessVenous thromboembolismFollow-Up Studiesmedicine.drug
researchProduct

Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design.

2014

Abstract Introduction and objectives Morbidity and mortality after admission for acute heart failure remain prohibitively high. In that setting, plasma levels of antigen carbohydrate 125 have shown to correlate with the severity of fluid overload and the risk of mortality and readmission. Preliminary data suggests a potential role of antigen carbohydrate 125 to guide therapy. The objective of this study is to evaluate the prognostic effect of an antigen carbohydrate 125-guided management strategy vs standard therapy in patients recently discharged for acute heart failure. Methods This is a multicenter, randomized, single-blind, efficacy trial study of patients recently discharged from acute…

AdultMalemedicine.medical_specialtyRandomizationTime FactorsRisk AssessmentAntigenCause of DeathRisk of mortalityMedicineHumansIn patientSingle-Blind MethodProspective StudiesIntensive care medicineAgedHeart Failurebusiness.industryStandard treatmentDisease ManagementCardiovascular AgentsGeneral MedicineMiddle Agedmedicine.diseasePrognosisPatient DischargeClinical trialSurvival RateSpainHeart failureCA-125 AntigenAcute DiseaseFemalebusinessCarbohydrate antigenBiomarkersFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia

2019

We analyzed the outcomes of 26 consecutive patients with acquired severe aplastic anemia (SAA) undergoing peripheral blood stem cell transplantation (PBSCT) with partial ex vivo T cell depletion with a targeted T cell dose from HLA-identical sibling donors. The median patient age was 37 years (range, 3 to 63 years). Four patients with uncontrolled pneumonia at the time of transplantation died, on days +1, +2, +21, and +26. All evaluable patients engrafted, with a median time to neutrophil recovery of 11 days (range, 10 to 14 days) and a median time to platelet recovery of 19 days (range, 8 to 53 days). Two patients had transient grade I acute graft-versus-host disease (GVHD) with skin invol…

AdultMalemedicine.medical_specialtySevere aplastic anemiaAdolescentT-LymphocytesT cellGraft vs Host DiseaseHuman leukocyte antigenSeverity of Illness IndexGastroenterologyDisease-Free SurvivalLymphocyte DepletionHLA AntigensInternal medicinemedicineHumansCumulative incidenceSiblingChildAllogeneic stem cell transplantation Ex vivo T cell depletion Matched sibling donor Severe aplastic anemiaEx vivo T cell depletionMatched sibling donorPeripheral Blood Stem Cell TransplantationTransplantationbusiness.industryHistocompatibility TestingSiblingsAnemia AplasticHematologyMiddle AgedAllograftsmedicine.diseaseSevere Aplastic AnemiaTissue DonorsAllogeneic stem cell transplantationSurvival RateTransplantationPneumoniasurgical procedures operativemedicine.anatomical_structureChild PreschoolAcute DiseasebusinessEx vivoFollow-Up StudiesBiology of Blood and Marrow Transplantation
researchProduct